Diabetes Market Research Reports & Industry Analysis

The markets for diabetes care products can be segmented as either monitoring/testing products or therapeutics products. Testing products can be further segmented by analyte for glucose, ketones, and microalbumin/albumin. Therapeutic products can also be further segmented as insulin, oral hypoglycemic agents and drugs to treat diabetic complications. Drugs to treat diabetic complications can further be segmented into antihypertensives, lipid-lowering drugs (for both cholesterol and triglycerides), antiarrhythmatic drugs and drugs to treat peripheral vascular diseases. Each segment of the diabetes-care market, therefore, has different dynamics and different emphases, despite the focus on a single condition (hyperglycemia) and its complications.

Glucose monitors have a major consumer-marketing component. While physicians may prescribe a monitor, the patient ultimately has the choice of which monitor s/he uses. Insulin provides very little consumer choice. The treatment regimen prescribed by the physician must be followed and there are very few market options. With Eli Lilly and Novo Nordisk being the two largest producers of insulin, it is highly likely that an insulin user will wind up using one of their products. As time goes by, the options of oral insulin and more intranasal insulin products may offer insulin dependent diabetics more variety in terms of products and delivery methods.

Hypoglycemic agents abound and vary in their composition and mode of action. For the most part, advanced cases of Type 2 diabetes require more than one of these drugs in order for the patient to maintain glycemic control. Because of the wide variety of these products, there is some room for pharmaceutical companies to influence diabetics toward using their products. In the end, the physician may have the last word, but that does not mean that the patient will stay with a physician who does not acquiesce to his/her wishes.

...Show More ...Show Less


Diabetes Industry Research & Market Reports

  • The 2025-2030 World Outlook for Proliferative Diabetic Retinopathy Treatments

    ... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More

  • The 2025-2030 World Outlook for Injectable Diabetes Drugs

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

  • The 2025-2030 World Outlook for Diabetic Retinopathy

    ... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More

  • The 2025-2030 World Outlook for Diabetic Retinopathy Therapeutics

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

  • The 2025-2030 World Outlook for External Tethered Insulin Pumps

    ... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More

  • The 2025-2030 World Outlook for Rapid Acting Insulin Analogs for Type 1 Diabetes

    ... year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of ... Read More

  • The 2025-2030 World Outlook for Continuous Glucose Monitoring Devices and Diabetes-Related Products

    ... estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. ... Read More

  • The 2025-2030 World Outlook for Diabetes Diagnostics

    ... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More

  • The 2025-2030 World Outlook for Diabetes Treatment Devices

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

  • The 2025-2030 World Outlook for Diabetic Assays

    ... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More

  • The 2025-2030 World Outlook for Digital Diabetes Management

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

  • The 2025-2030 World Outlook for GLP-1 Agonists for Type 2 Diabetes

    ... given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative ... Read More

  • The 2025-2030 World Outlook for Metabolic Disorder Therapeutics

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

  • The 2025-2030 World Outlook for External Insulin Pumps

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

  • The 2025-2030 World Outlook for Anti-Vascular Endothelial Growth Factor Therapy (Anti-VEGF) for Non-Infectious Macular Edema

    ... 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of ... Read More

  • The 2025-2030 World Outlook for Diabetic Retinopathy Treatments

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

  • The 2025-2030 World Outlook for Diabetic Socks

    ... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More

  • The 2025-2030 World Outlook for Diabetic Ulcer Treatments

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

  • The 2025-2030 World Outlook for Diabetes Diagnosis, Treatment, and Drug Delivery Devices

    ... estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. ... Read More

  • The 2025-2030 World Outlook for Diabetes Monitoring and Diagnostic Devices

    ... the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow ... Read More

  • The 2025-2030 World Outlook for Diabetes Monitoring Devices

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

  • The 2025-2030 World Outlook for Diabetic Foot Ulcer Therapeutics

    ... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More

  • The 2025-2030 World Outlook for Diabetic Confectionery Foods

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

  • The 2025-2030 World Outlook for Diabetic Nephropathy Treatments

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

  • The 2025-2030 World Outlook for Pen Insulin Syringes

    ... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More

Research Assistance

Live help

Join Alert Me Now!

Sign Up

Find out more on our blog
Cookie Settings